Form 8-K · Current Report · Filed 2025-11-21
Abbott Laboratories Announces Blackout Period for Employee Benefit Plans
Abbott Laboratories has announced a temporary suspension of trading under its employee benefit plans due to administrative changes, including changes to the recordkeeper, trustee, and custodian.
- Filer
- Abbott Laboratories ABT · NYSE
- Filed
- Accession
- 0001104659-25-114995
- CIK
- 0000001800
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The blackout period, which is expected to begin on December 24, 2025, and end during the week of January 11, 2026, restricts plan participants from engaging in transactions involving the assets held in their plan accounts. A notice regarding the blackout period was sent to directors and executive officers on November 21, 2025.
Items reported
Reported Item
Financial Statements and Exhibits
Market reaction
Close before filing
$123.97
Next session
+2.6%
Since filing
-14.7%
Latest close
$105.70
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABT reporting the same item, with the next session's move:
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Never miss another ABT filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.